Department of Pediatrics, University of Alberta, Edmonton Clinic Health Academy, 11405-87 Avenue, Edmonton, AB, Canada, T6G 1C9
Child Health, Glenrose Rehabilitation Hospital, 10230 111th Avenue, Edmonton, AB, Canada, T5G 0B7.
BMJ. 2018 May 21;361:k1674. doi: 10.1136/bmj.k1674.
Autism spectrum disorder (ASD) has a variety of causes, and its clinical expression is generally associated with substantial disability throughout the lifespan. Recent advances have led to earlier diagnosis, and deep phenotyping efforts focused on high risk infants have helped advance the characterization of early behavioral trajectories. Moreover, biomarkers that measure early structural and functional connectivity, visual orienting, and other biological processes have shown promise in detecting the risk of autism spectrum disorder even before the emergence of overt behavioral symptoms. Despite these advances, the mean age of diagnosis is still 4-5 years. Because of the broad consistency in published guidelines, parameters for high quality comprehensive assessments are available; however, such models are resource intensive and high demand can result in greatly increased waiting times. This review describes advances in detecting early behavioral and biological markers, current options and controversies in screening for the disorder, and best practice in its diagnostic evaluation including emerging data on innovative service models.
自闭症谱系障碍(ASD)有多种成因,其临床表现通常与终生的显著残障相关。随着研究的进展,自闭症谱系障碍能更早地被诊断出来,对高风险婴儿的深入表型分析也有助于推动早期行为轨迹的特征描述。此外,一些生物标志物,如早期结构和功能连接、视觉定向等生物过程的测量,在检测自闭症谱系障碍的风险方面具有很大的潜力,甚至在明显的行为症状出现之前就可以检测到。尽管取得了这些进展,但自闭症谱系障碍的平均诊断年龄仍为 4-5 岁。由于发表的指南中有广泛的一致性,高质量的综合评估参数是可用的;然而,这种模式需要大量资源,高需求可能导致等待时间大大延长。本综述描述了早期行为和生物标志物检测方面的进展,目前对该疾病进行筛查的选择和争议,以及其诊断评估的最佳实践,包括创新服务模式的新兴数据。